PremiumThe FlyTG Therapeutics reports Q1 EPS 3c, consensus 17c Positive Revenue Outlook and Strategic Investments Reinforce Buy Rating for TG Therapeutics Buy Rating for TG Therapeutics Driven by Promising Briumvi Data and Strong Revenue Projections PremiumRatingsTG Therapeutics: Strategic Positioning and Growth Potential Drive Buy Rating Buy Rating Affirmed for TG Therapeutics Amid Strong Briumvi Performance and Growth Prospects TG Therapeutics call volume above normal and directionally bullish PremiumRatingsStrong Financial Performance and Promising Outlook Drive Buy Rating for TG Therapeutics TG Therapeutics Reports Strong 2024 Financial Results and Outlook TG Therapeutics Earnings Call: Strong Growth Amid Challenges